Anixa Biosciences Inc

Anixa Biosciences has appointed Dr. Carmen Guerra of the University of Pennsylvania to its Cancer Business Advisory Board. Dr. Guerra is the Ruth C. and Raymond G. Perelman Professor of Medicine and Professor of Biostatistics and Epidemiology at the Perelman School of Medicine at the University of Pennsylvania, and serves as Associate Director of Community Outreach and Engagement for the Abramson Cancer Center. Chief Executive Dr. Amit Kumar said her guidance will help as the company advances its breast cancer vaccine into a Phase 2 clinical trial and continues a Phase 1 trial of its ovarian cancer CAR-T therapy. Dr. Guerra's research focuses on increasing participation in cancer screening and clinical trials, and she oversees the Penn Medicine Colorectal Cancer Screening Navigation Program and the Breast and Cervical Cancer Early Detection Program. She is a member of the American Cancer Society Clinical Guidelines Development group and served on the society's national board of directors from 2016 to 2023 as Board Scientific Officer.

Anixa Biosciences is advancing a diversified oncology pipeline that includes a breast cancer vaccine, an ovarian cancer vaccine, and a novel CAR-T therapy for ovarian cancer, with plans to expand into lung, colon, and prostate cancers. The breast cancer vaccine showed a favorable safety profile and generated immune responses in 74% of participants in a phase I study, and the company has partnered with Cytovance Biologics to manufacture clinical materials for a planned phase II study. Its ovarian cancer CAR-T therapy, lira-cel, has demonstrated encouraging safety data in an ongoing phase I study with no dose-limiting toxicities and preliminary signs of clinical activity. Anixa also received a notice of allowance from the Canadian Intellectual Property Office for a patent covering its ovarian cancer vaccine technology. Over the past three months, Anixa shares have risen 4.2%, outperforming the industry's 0.6% growth, and the company carries a Zacks Rank of 2, or Buy, with loss per share estimates for the current year narrowing from 36 cents to 31 cents over the past 60 days.